Abstract Novel antibiotics, active against acid-fast bacteria, caprazamycins, were isolated from the culture broth of Streptomyces sp. MK730-62F2. The planar structures of the compounds were determined by 2D NMR spectroscopic study. Furthermore, the absolute structure of caprazamycin B (2) was established by NMR spectroscopy and X-ray crystallography of its degradation products and by total synthesis of the 5-amino-5-deoxy-D-ribose moiety. In the course of degradation studies of 2 under alkaline and acidic conditions, we obtained the two core components, caprazene (11) and caprazol (14), respectively, in high yield.
(4b-H) to d 171.0 (C-5b) supported partial structure d. Moreover, the cross peaks from d 6.34 (1c-H) to d 70.2 (C5c), from d 3.50 (2c-OCH 3 ) to d 76.0 (C-2c), from d 3.53 (3c-OCH 3 ) to d 80.9 (C-3c) and from d 3.56 (4c-OCH 3 ) to d 81.6 (C-4c) supported partial structure e.
The connections between the five partial structures (a, b, c, d and e) and two N-CH 3 groups were revealed by the HMBC spectrum as shown in Fig. 3 . The anomeric proton at d 5.62 (1Љ-H) was coupled with the methine carbon bearing an oxgen atom at d 76.2 (C-5Ј). The methine proton bearing an oxgen atom at d 5.75 (3ٞ-H) was coupled with the carbonyl carbon at d 169.7 (C-1a). The anomeric proton at d 6.34 (1c-H) of the sugar moiety e was coupled with the carbonyl carbon at d 171.0 (C-5b). The Nmethyl protons at d 2.72 (5ٞ-NCH 3 ) were coupled with the methine carbon at d 63.8 (C-6ٞ) and the methylene carbon at d 57.1 (C-4ٞ). Moreover, the N-methyl protons at d 3.35 (8ٞ-NCH 3 ) were coupled with the methine carbon at d 63.9 (C-2ٞ) and the carbonyl carbon at d 170.8 (C-7ٞ). Based on the above observations, the planar structure of caprazamycin B (2) was elucidated as shown in Fig. 3 .
Stereochemistry of Caprazamycin B
The absolute structure of 2 was determined by NMR spectroscopy and X-ray crystallography of its degradation products, including the two core components.
Acid hydrolysis of 2 with 80% trifluoroacetic acid in methanol at room temperature gave the aglycone, designated as caprazamycin B1 (8) and 2,3,4-tri-O-methyl-L-rhamnose (9) in high yield, respectively (Scheme 1). To ascertain the L-rhamnose structure of 9, the sugar was converted to the known methyl glycosides. Treatment of 9 with acidic methanol at 50°C gave a mixture of the a -glycoside, methyl 2,3,4-tri-O-methyl-a -Lrhamnopyranoside (10a), and its b-anomer 10b. Isolation of the anomeric mixture by column chromatography gave 10a as a syrup, of which the physico-chemical properties were identical with those of the authentic sample [6ϳ8] . The glycosidic linkage of L-rhamnose to caprazamycin B (2) was deduced from the 13 C-NMR spectra. The 1 J C-H coupling constant (167 Hz) of the anomeric carbon of aglycoside 10a was larger than those of the b-anomer 10b ( 1 J C-H ϭ153 Hz). On the other hand, the anomeric carbon of 2,3,4-tri-O-methylated rhamnose in 2 showed a larger value ( 1 J C1c-H1c ϭ174 Hz, in dimethylsulfoxide-d 6 ). Because it is known that introduction of an acyl group instead of a methoxyl group at an anomeric position increases the 1 J C-H values to some extent [9] , the mode of sugar linkage in 2 is regarded as a.
Further hydrolysis of 8 with 80% aqueous acetic acid at 70°C gave the unsaturated compound 11, designated as caprazene, and the diacid 12 in high yield, respectively. The core component 11 was also obtained quantitatively by direct hydrolysis of 2 under the same conditions. The two carboxyl groups of 12 were treated with 4-bromoaniline in the presence of bis(2-oxo-3-oxazolidinyl)phosphinic chloride (BOP-Cl) to give the bromoanilide 13 in 70% yield, which was crystallized from its acetone solution. The ORTEP drawing of 13 is shown in Fig. 4 . On the basis of X-ray structure analysis of 13, the configurations at C-3a and C-3b of caprazamycin B (2) were determined to be S and S, respectively.
Alkaline degradation studies of 2 also gave another core component. Treatment of 2 with aqueous ammonia in N,Ndimethylformamide for 4 days at room temperature gave the deacylated compound 14 quantitatively, which was designated as caprazol (Scheme 2). Crystallization of 14 from aqueous methanol afforded prisms suitable for X-ray structure analysis. The ORTEP drawing of caprazol (14) is shown in Fig. 5 . To elucidate the absolute structure of the ribose moiety of 2, the reference methyl 5-amino-5-deoxya-and b-D-ribofuranosides (18a and 18b) were prepared from 5-azido-5-deoxy-1,2-O-isopropylidene-a -D-ribose (15) [10] in two steps (Scheme 3). Methanolysis of 15 in the presence of cation-exchange resin gave an anomeric mixture (1 : 2.9) of methyl glycosides (16a and 16b) in 63% yield, along with methyl 5-azido-5-deoxy-2,3-Oisopropylidene-b-D-ribofuranoside (17) [10, 11] . Treatment of a mixture of 16a and 16b with triphenylphospine in aqueous tetrahydrofuran gave an anomeric mixture of the free amino sugars (18a and 18b), quantitatively. Separation of these anomers was successfully performed by silica gel column chromatography.
On the other hand, caprazene (11) was solvolyzed in boiling methanol in the presence of cation-exchange resin for 14 hours to give a mixture (1 : 2.2) of 18a and 18b in 51% yield. The b -glycoside 18b isolated, was in all respects identical with the reference sample prepared from 15. The agreement on the specific rotation value between the both compounds proved that the 5-amino-5-deoxyribose moiety in caprazamycin B (2) is the D-sugar.
Finally, based on the results described above, the stereochemistry of 2 was established to be C-5Ј (S), C-2ٞ (S), C-3ٞ (S), C-6ٞ (S), C-3a (S) and C-3b (S) as shown in Fig. 1 .
The CPZs are structurally related to lipo-uridyl antibiotics such as liposidomycins, muraymycins [12] and capuramycins [13ϳ15], which have been shown to be specific inhibitors of a bacterial translocase. Liposidomycins are especially, close analogs of CPZs, differing in the absence of the tri-O-methyl-L-rhamnose moiety and the dissimilarity for configuration of the acylated side chain at the C-3a position [5] . These nucleoside antibiotics comprise a novel type of drugs having the inhibitory activity against bacterial cell wall biosynthesis.
In the degradation studies of caprazamycins, we obtained efficiently the two core components, caprazene (11) and caprazol (14) . These compounds were considered to be attractive precursors for the synthesis of caprazamycin analogs. Semi-synthetic antibiotics derived from 11 or 14 and their biological activities will be reported later. 
Experimental

General Methods
Melting points were determined on a Kofler block and are uncorrected. Optical rotations were determined with a Perkin-Elmer 241 polarimeter. UV spectra were measured with a Hitachi 557 spectrophotometer. IR spectra were recorded on a Horiba FT-210 Fourier transform infrared spectrometer.
1
H and 13 C NMR spectra were measured with a JEOL JNM-A500 and/or Bruker AVANCE 500 spectrometer, using TMS as an internal reference. Mass spectra were recorded using a JEOL JMS-SX102 (HR-FAB) and/or JEOL JMS-T100LC (HR-ESI) spectrometer. X-Ray crystallographic measurements were made on Rigaku AFC7R diffractometer with graphite monochromated Cu-Ka radiation and a rotation anode generator. All calculations of the measurements were performed using the teXsan crystallographic software package of Molecular Structure Corporation. TLC was performed on Kieselgel 60 F 254 (Merck), and column chromatography was carried out on Kieselgel 60 (Merck).
Caprazamycin B1 (8) and 2,3,4-tri-O-methyl-Lrhamnose (9)
A solution of 2 (301 mg, 0.263 mmol) in 4.5 ml of trifluoroacetic acid -MeOH (4 : 1) was kept for 1 hour at room temparature. Concentration gave a syrup, which was added to diethyl ether. The precipitate obtained was filtered and thoroughly washed with diethyl ether to give a colorless solid of 8 (278.4 mg, 99% as the mono CF 3 COOH salt). The filtrate and washings were combined and concentrated to give 9 (52.5 mg, 97%) as a syrup. 
Methyl 2,3,4-tri-O-methyl-a a-and b b-Lrhamnopyranoside (10a and 10b)
To a solution of 9 (96.5 mg, 0.468 mmol) in MeOH (1.5 ml) was added sulfuric acid (30 m l, 0.563 mmol) and the solution was heated for 5 hours at 50°C. TLC (1 : 1 hexane -diethyl ether) of the solution showed two spots at Rf 0.25 (10a, major) and 0.15 (10b) (cf. 9: Rf 0.05). The solution was concentrated to a low volume, diluted with CHCl 3 , and washed with aq NaHCO 3 and water. The organic layer was dried (Na 2 SO 4 ) and concentrated to give a syrupy mixture (89.7 mg, 87%) of 10a and 10b (the ratio was 5 : 1; determined from the 
Caprazene (11)
A solution of 2 (200 mg, 0.174 mmol) in 80% aq AcOH (6 ml) was heated for 2 hours at 70°C. Concentration gave a syrup, which was added to acetone. 
(3S,3R)-3-(4-Carboxy-3-methylbutanoyloxy)-14-methylpentadecanoic Acid (12) and (11)
A solution of 8 (240 mg, 0.224 mmol as the mono CF 3 COOH salt) in 80% aq AcOH (6 ml) was heated for 2 hours at 70°C. TLC (2 : 1 : 1 EtOAc -1-PrOH -20% aq AcOH) of the solution showed two spots at Rf 0.95 (12) and 0.05 (11) (cf. 8: Rf 0.35). Concentration gave a residue, which was washed with acetone to give 11 (123.5 mg, 99%). The washings were concentrated and the resulting syrup was extracted with CHCl 3 . The extract was washed with water and concentrated to give 12 (82.5 mg, 92%) as a colorless syrup. (1H, m, 2Јb-H), 2.45 (1H, m, 3Ј-H 
Caprazol (14)
To a solution of 2 (150 mg, 0.131 mmol) in DMF (1.5 ml) was added 28% aq NH 3 (1.5 ml), and the mixture was stirred for 4 days at room temperature. Filtration followed by concentration in vacuo gave a residue, which was thoroughly washed with acetone to give 14 (74.7 mg, 99%) as a colorless solid. An analytical sample (prism) was prepared by crystallization from MeOH -H 2 X-Ray Crystallographic Analysis of 13 A colorless prism crystal described for 13, having approximate dimensions of 0.02ϫ0.18ϫ0.40 mm was chosen for X-ray crystallography. . Of the 3523 reflections which were collected, 3118 were unique. The intensities of three representative reflections were measured after every 150 reflections. Over the course of data collection, the standards decreased by 6.4%. A linear correction factor was applied to the data to account for this phenomenon. The structure was solved by direct method (SIR92) [16] and expanded using a Fourier technique (DIRDIF94) [17] . The non-hydrogen atoms were refined anisotropically. Hydrogen atoms were included but not refined. The final cycle of full-matrix least-squares refinement was based on 2803 observed reflections and 379 variable parameters and converged with unweighted and weighted agreement factors of Rϭ0.089 and Rwϭ0.134. The maximum and minimum peaks on the final difference Fourier map corresponded to 0.37 and Ϫ0.39e Ϫ /Å 3 , respectively. The absolute configuration of the molecule was determined based on Flack parameter, Ϫ0.076 (59).
X-Ray Crystallographic Analysis of 14
A colorless prism crystal described for 14, having approximate dimensions of 0.06ϫ0.06ϫ0.30 mm was chosen for X-ray crystallography. The crystal data are as follows: Empirical formula C 22 
